

Title (en)

COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIOVASCULAR DISEASE

Title (de)

KOMBINATIONSTHERAPIE ZUR VERMINDERUNG DER MIT HERZ-KREISLAUFERKRANKUNGEN EINHERGERGENDEN RISIKEN

Title (fr)

TRAITEMENT COMBINE DESTINE A REDUIRE LES RISQUES DE MALADIES CARDIO-VASCULAIRES

Publication

EP 0946178 A4 20030507 (EN)

Application

EP 97941644 A 19970915

Priority

- GB 9621970 A 19961022
- US 9716388 W 19970915
- US 2658196 P 19960918

Abstract (en)

[origin: WO9811896A1] The instant invention involves a combination therapy and pharmaceutical compositions comprised of a therapeutically effective amount of a cholesterol reducing agent such as an HMG-CoA reductase inhibitor in combination with a platelet aggregation inhibitor which is useful for inhibiting platelet aggregation, for inhibiting the formation of thrombotic occlusions, and for treating, preventing and reducing the risk of occurrence of cardiovascular and cerebrovascular events and related vaso-occlusive disorders.

IPC 1-7

A61K 31/505; **A61K 31/44**; **A61K 31/35**; **A61K 31/225**

IPC 8 full level

A61K 31/351 (2006.01); **A61K 31/395** (2006.01); **A61K 31/4015** (2006.01); **A61K 31/404** (2006.01); **A61K 31/41** (2006.01); **A61K 31/4365** (2006.01); **A61K 31/44** (2006.01); **A61K 31/445** (2006.01); **A61K 31/454** (2006.01); **A61K 31/455** (2006.01); **A61K 31/495** (2006.01); **A61K 31/497** (2006.01); **A61K 31/519** (2006.01); **A61K 31/551** (2006.01); **A61K 31/5513** (2006.01); **A61K 31/60** (2006.01); **A61K 38/00** (2006.01); **A61K 45/06** (2006.01); **A61P 7/02** (2006.01); **A61P 9/10** (2006.01)

CPC (source: EP)

A61K 45/06 (2013.01); **A61P 7/02** (2017.12); **A61P 9/10** (2017.12)

Citation (search report)

- [PX] WO 9738694 A1 19971023 - MERCK & CO INC [US], et al
- [XDY] US 5281585 A 19940125 - DUGGAN MARK E [US], et al
- [YD] US 5318899 A 19940607 - SCARBOROUGH ROBERT M [US], et al
- [X] TANVEER RAB S ET AL: "CORONARY ANEURYSMS AFTER STENT PLACEMENT: A SUGGESTION OF ALTERED VESSEL WALL HEALING IN THE PRESENCE OF ANTI-INFLAMMATORY AGENTS", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, XX, XX, vol. 18, no. 6, 15 November 1991 (1991-11-15), pages 1524 - 1528, XP001083633, ISSN: 0735-1097
- [YD] ZHANG L-H ET AL: "THE CHIRAL SPECIFIC SYNTHESIS OF DMP 754, A PLATELET GP IIB/IIIA ANTAGONIST", TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 37, no. 26, 1996, pages 4455 - 4458, XP002071215, ISSN: 0040-4039
- [Y] NOTARBARTOLO A ET AL: "INHIBITION OF THROMBOXANE BIOSYNTHESIS AND PLATELET FUNCTION BY SIMVASTATIN IN TYPE IIA HYPERCHOLESTEROLEMIA", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, XX, XX, vol. 15, no. 2, February 1995 (1995-02-01), pages 247 - 251, XP001037365, ISSN: 1079-5642
- [Y] MALYSZKO JOLANTA ET AL: "Effects of short-term treatment with mevalotin on platelet aggregation, fibrinolysis, peripheral serotonergic system and serum lipids in Japanese monkeys.", THROMBOSIS RESEARCH, vol. 81, no. 3, 1996, pages 397 - 402, XP002233543, ISSN: 0049-3848
- [Y] ARRIGONI-MARTELLI E: "FIRST EUROPEAN CONGRESS OF PHARMACOLOGY", DRUGS OF TODAY / MEDICAMENTOS DE ACTUALIDAD, J.R. PROUS S.S.A. INTERNATIONAL PUBLISHERS, ES, vol. 31, no. 8, December 1995 (1995-12-01), pages 635 - 637, XP001061459, ISSN: 0025-7656
- [A] CASTAIGNE A ET AL: "TRAITEMENT MEDICAL DES PATIENTS AYANT UN ANGOR STABLE", REVUE DU PRATICIEN, J.B. BAILLIERE, PARIS, FR, vol. 45, no. 17, 1975, pages 2161 - 2167, XP001061466, ISSN: 0035-2640
- See references of WO 9811896A1

Designated contracting state (EPC)

AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

DOCDB simple family (publication)

WO 9811896 A1 19980326; AU 4350897 A 19980414; AU 723315 B2 20000824; CA 2265827 A1 19980326; EP 0946178 A1 19991006; EP 0946178 A4 20030507; JP 2001500875 A 20010123

DOCDB simple family (application)

US 9716388 W 19970915; AU 4350897 A 19970915; CA 2265827 A 19970915; EP 97941644 A 19970915; JP 51481598 A 19970915